These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 22612026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reversal of a dabigatran overdose: what are possible options?
    Ratanapo S, Ungprasert P, Srivali N, Cheungpasitporn W, Bischof EF.
    Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23974270
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S, Nilsson CU, Engström M, Ostrowski SR, Johansson PI.
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [Abstract] [Full Text] [Related]

  • 6. Dabigatran: life-threatening bleeding.
    Prescrire Int; 2013 Feb; 22(135):41-3. PubMed ID: 23444501
    [Abstract] [Full Text] [Related]

  • 7. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
    Lillo-Le Louët A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM.
    Thromb Haemost; 2012 Sep; 108(3):583-5. PubMed ID: 22782645
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bleeding risk with dabigatran in the frail elderly.
    Harper P, Young L, Merriman E.
    N Engl J Med; 2012 Mar 01; 366(9):864-6. PubMed ID: 22375994
    [No Abstract] [Full Text] [Related]

  • 10. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
    Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C.
    Hamostaseologie; 2012 Mar 01; 32(4):294-305. PubMed ID: 23114798
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
    Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, Eris JM, Tran H, Patel JP, Roberts DM.
    Clin Toxicol (Phila); 2015 Mar 01; 53(3):156-63. PubMed ID: 25661675
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hemorrhagic complications associated with dabigatran use.
    Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS.
    Clin Toxicol (Phila); 2012 Nov 01; 50(9):854-7. PubMed ID: 22970730
    [Abstract] [Full Text] [Related]

  • 17. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
    Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D.
    Br J Haematol; 2015 May 01; 169(4):603-4. PubMed ID: 25425051
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb 01; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.